NCI Director Broder, Going On 3rd Year, Examines Issues Of Funding, Priorities, For Institute’s Future
In Brief: Tipping Resigns Forom ACS; Vaughan Joins UAB BMT Program; PCI Recruits Ball, Finn, Mirro
‘Be Careful We’re Not Fighting Old Battles’ On Study Section Issue
‘We Cannot Tolerate One Third Reduction In Centers. Prevention, Clinical Trials Programs’
“NIH Reveres, Honors, respects And Defends One And Only One Mechanisms’ – R01s
Centers Program Needs ‘Innovative Additions’ Such as SPORE Grants
Broder Not Satisfied With Mortality STATS On Three Major Cancers
Trending Stories
- FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- Beyond the $500B Stargate Project: The frontier of AI in oncology beckons
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Tracking Trump’s early impact on cancer policy
Research and care disrupted, NCI programs face unpredictable future - Felix Feng, GU cancer researcher who made fundamental discoveries in genomics, dies at 48
- Trump 2016: A look back at the 45th president’s impact on oncology